Use of the new dengue vaccine Qdenga in Germany For whom and when?

被引:0
|
作者
Kling, Kerstin [1 ]
Kuelper-Schiek, Wiebe [1 ]
机构
[1] Robert Koch Inst, Abt Infekt Epidemiol 3, Fachgebiet Impfpravent, Berlin, Germany
关键词
Disease transmission; infectious; Travellers; Vaccine effectiveness; Virologically confirmed dengue; Antibody-dependent enhancement; HEALTHY-CHILDREN; EFFICACY; PHASE-3; RISK;
D O I
10.1007/s00112-024-01946-4
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Infections with mosquito-borne pathogens are on the rise worldwide, with dengue virus (DENV) infections leading the way. In the last two decades the World Health Organization (WHO) has recorded a tenfold increase in dengue cases worldwide, with 5.2 million cases reported in 2019. Until now, travellers have only been able to protect themselves from mosquito bites by taking individual measures (repellents, wearing long clothing). Vector control measures in endemic areas (e.g., by reducing open water reservoirs) reduce the local reproduction and spread of mosquitos. Since spring 2023, a dengue vaccine is available in Germany that is approved for people aged 4 years and older. The Standing Committee on Vaccination (STIKO) at the Robert Koch Institute recommends its use for travellers before exposure in the endemic country if they have previously had a laboratory confirmed DENV infection. As it cannot be ruled out based on the currently available data that the vaccination may lead to an increased severity of infection in dengue-naive people, the STIKO does not currently recommend the vaccination for people who have not yet had a confirmed DENV infection.
引用
收藏
页码:418 / 425
页数:8
相关论文
共 50 条
  • [41] New dengue fever vaccine to undergo human trials
    不详
    EXPERT REVIEW OF VACCINES, 2010, 9 (11) : 1247 - 1247
  • [43] The future looks bright for the production of a new dengue vaccine
    Rees, Jenaid
    EXPERT REVIEW OF VACCINES, 2013, 12 (03) : 247 - 247
  • [44] NEW UTILITY GENERATING PLANTS: WHEN, WHERE AND BY WHOM.
    Smock, Robert
    Reynolds, Mona
    Power Engineering (Barrington, Illinois), 1987, 91 (04): : 15 - 21
  • [45] DICTIONARIES, NEW AND OLD - WHO PLAGIARIZES WHOM, WHY AND WHEN
    BURCHFIELD, R
    ENCOUNTER, 1984, 63 (03): : 10 - 19
  • [46] The HRD Decision-Which PARP Inhibitor to Use for Whom and When
    Kohn, Elise C.
    Lee, Jung-min
    Ivy, S. Percy
    CLINICAL CANCER RESEARCH, 2017, 23 (23) : 7155 - 7157
  • [47] Dengue pre-vaccination screening test evaluation for the use of dengue vaccine in an endemic area
    Limothai, Umaporn
    Tachaboon, Sasipha
    Dinhuzen, Janejira
    Hunsawong, Taweewun
    Ong-ajchaowlerd, Prapapun
    Thaisomboonsuk, Butsaya
    Fernandez, Stefan
    Trongkamolchai, Supachoke
    Wanpaisitkul, Mananya
    Chulapornsiri, Chatchai
    Tiawilai, Anongrat
    Tiawilai, Thawat
    Tantawichien, Terapong
    Thisyakorn, Usa
    Srisawat, Nattachai
    PLOS ONE, 2021, 16 (09):
  • [48] Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas
    Letson, G. William
    Singhasivanon, Pratap
    Fernandez, Eduardo
    Abeysinghe, Nihal
    Jose Amador, Juan
    Margolis, Harold S.
    Edelman, Robert
    HUMAN VACCINES, 2010, 6 (10): : 802 - 809
  • [49] Is new dengue vaccine efficacy data a relief or cause for concern?
    Stephen J. Thomas
    npj Vaccines, 8
  • [50] Is new dengue vaccine efficacy data a relief or cause for concern?
    Thomas, Stephen J.
    NPJ VACCINES, 2023, 8 (01)